Currently, IDH mutation status is assessed by immunohistochemistry (IHC) or DNA sequencing techniques of the tumor specimen, which is invasive, and given the morphological heterogeneity and invasiveness of high-grade gliomas, the full extent of intratumoral phenotypic/genotypic heterogeneity may not be represented in the tumor specimen. The gene discussed is IDH2; the disease is neoplasm.